Cleared Traditional

INAMED RHEMO-D (TM) DILATOR (K894618) - FDA 510(k) Clearance

Class I Gastroenterology & Urology device.

K894618 · Inamed Development Co. · Gastroenterology & Urology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 1990
Decision
182d
Days
Class 1
Risk

K894618 is an FDA 510(k) clearance for the INAMED RHEMO-D (TM) DILATOR. Classified as Dilator, Rectal (product code FFP), Class I - General Controls.

Submitted by Inamed Development Co. (Carpinteria, US). The FDA issued a Cleared decision on January 18, 1990 after a review of 182 days - an extended review cycle.

This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.5450 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Gastroenterology & Urology review framework, consistent with the majority of Class II 510(k) submissions.

View all Inamed Development Co. devices

Submission Details

510(k) Number K894618 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 20, 1989
Decision Date January 18, 1990
Days to Decision 182 days
Submission Type Traditional
Review Panel Gastroenterology & Urology (GU)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
52d slower than avg
Panel avg: 130d · This submission: 182d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code FFP Dilator, Rectal
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 876.5450
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.